Tag: NKTR

Finance

Big Movers: Nektar Therapeutics (NASDAQ:NKTR), Harmonic (NASDAQ:HLIT), Apollo Global Management (NYSE:APO), PartnerRe Ltd. (NYSE:PRE), Oil States International Inc. (NYSE:OIS)

On 31 JULY Nektar Therapeutics (NASDAQ:NKTR) last released its earnings data on Thursday. The company reported ($0.26) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.37) by $0.11. The company had revenue of $28.50 million for the quarter, compared to the consensus estimate of $19.76 million. During the same quarter in the prior year, the company posted ($0.37) earnings per share. The … Continue reading Big Movers: Nektar Therapeutics (NASDAQ:NKTR), Harmonic (NASDAQ:HLIT), Apollo Global Management (NYSE:APO), PartnerRe Ltd. (NYSE:PRE), Oil States International Inc. (NYSE:OIS)

Adam Keintzel
Finance

Best Stocks – La Jolla Pharmaceutical Company (NASDAQ:LJPC) , Nektar Therapeutics (NASDAQ:NKTR) , International Tower Hill Mines (NYSEMKT:THM) , Lions Gate Entertainment (NYSE:LGF)

In a research report released on Wednesday, Noble Financial lifted price target for La Jolla Pharmaceutical Company (NASDAQ:LJPC) stock from $34 per share to $38 per share. La Jolla Pharmaceutical Company (NASDAQ:LJPC) stock performance was 1.88% in last session and finished the day at $10.85. Traded volume was 271,034.00million shares in the last session and the average volume of the stock remained 127.48K shares. The … Continue reading Best Stocks – La Jolla Pharmaceutical Company (NASDAQ:LJPC) , Nektar Therapeutics (NASDAQ:NKTR) , International Tower Hill Mines (NYSEMKT:THM) , Lions Gate Entertainment (NYSE:LGF)

John Bellich
Finance

Biotech Volatile Stocks: Incyte Corporation (NASDAQ:INCY), Halozyme Therapeutics (NASDAQ:HALO), Sangamo Biosciences (NASDAQ:SGMO), Nektar Therapeutics (NASDAQ:NKTR)

The only therapy currently approved by the Food and Drug Administration to treat myelofibrosis, a disorder where abnormal blood cells build up inside a patient’s bone marrow, is Incyte (NASDAQ:INCY) and Novartis’ Jakafi (known as Jakavi outside the U.S.), which is a JAK2 inhibitor. JAK2 is an enzyme that plays a key role in signal transduction; therefore, blocking JAK2 can inhibit the development cytokines that … Continue reading Biotech Volatile Stocks: Incyte Corporation (NASDAQ:INCY), Halozyme Therapeutics (NASDAQ:HALO), Sangamo Biosciences (NASDAQ:SGMO), Nektar Therapeutics (NASDAQ:NKTR)

Mark Doerr
Finance

Market Movers: JD.com, Inc. (NASDAQ:JD), Nektar Therapeutics (NASDAQ:NKTR), Teradata Corporation (NYSE:TDC), Sealed Air Corporation (NYSE:SEE), Cedar Fair, L.P. (NYSE:FUN)

JD.com Inc. (NASDAQ:JD) sank the most yesterday since its U.S. debut after Asia’s second-largest e-commerce operator provided a fourth-quarter sales forecast that fell short of investors’ heightened expectations. JD.com, Inc. (NASDAQ:JD) belongs to Technology sector. Its net profit margin is -11.90% and weekly performance is -4.76%. On last trading day company shares ended up $25.00. JD.com, Inc. (NASDAQ:JD) distance from 50-day simple moving average (SMA50) … Continue reading Market Movers: JD.com, Inc. (NASDAQ:JD), Nektar Therapeutics (NASDAQ:NKTR), Teradata Corporation (NYSE:TDC), Sealed Air Corporation (NYSE:SEE), Cedar Fair, L.P. (NYSE:FUN)

Chris Lewis